
Gordon Welty

This is the second of a series of articles on the development of a GXP training system. The first was paper was titled “Developing a New Employee Orientation Program for GXP Compliance,” and was published in the Journal of GXP Compliance, Vol. 13, No. 3 (Summer 2009), pp. 82-92. The present article discusses continuing current good manufacturing practice (CGMP) training in four sections. The first section reviews statements taken from regulations and guidances about continuing GMP training, made by the US Food and Drug Administration and other regulatory bodies. The interpretive nature of these statements, and the role that risk assessment plays in organizational response to gaps (deviations) between the statements and ongoing behavior, are stressed. The second section addresses the topic of individuals who are qualified to deliver the continuing GMP training, presenting two approaches to qualifying trainers—a formal approach such as a GMP train-the-trainer program and an experiential approach. While the experiential approach is cheaper than the formal approach, the formal approach has the merit of reducing variation in employee performance, as well as facilitating root cause analysis in case of deviations. The third section reviews major sources of topics that are available for continuing CGMP training, including regulations in 21 CFR 211, written procedures required by these regulations, and topics mentioned in FDA guidances, FDA warning letters, and the organization’s own records of deviations, investigations, corrective actions and preventive actions, and quality complaints. The final section reviews a major logistical issue in the delivery of continuing CGMP training: the frequency with which this training should be scheduled. FDA recommends training more frequently than just an annual basis.

INTRODUCTION

Every organization in regulated industry must train its employees. This training is scheduled in several ways. There is a basic scheduling distinction between training that is delivered in response to a perceived deficiency in performance or qualification, and training delivered according to the calendar. Training according to deficiency in performance or qualification includes new employee orientation (NEO), training for business process redesign and standard operating procedure (SOP) revision, and most technical training. In each case, trainees lack skill, information, or motivation that can be remedied by the training intervention.

Training according to the calendar includes much of regulatory training—the periodic refresher training that is mandated in business ethics, non-harassment policies, non-discrimination policies, a number of Occupational Safety and Health Administration (OSHA) regulations (1), and current good manufacturing practice (CGMP) regulations. As will become clear in the case of the US Food and Drug Administration regulations, refresher training may be scheduled more frequently than on an annual basis, which is why the regulations and guidance refer to “continuing” CGMP training rather than referring to “annual CGMP refresher training.”

The decisions that are made about either kind of training are informed by an implicit or explicit business risk assessment. The level of top-down support and the scheduling of continuing CGMP training reflect a business risk assessment made by various decision makers in the organization. Moreover, decisions about the content of the training, in contrast to mandate and schedule, may also be informed by a quality risk assessment, an assessment in terms of risk to the safety, identity, strength, purity, and quality (SISPQ) of the product (2).
Consider an example of business risk assessment, as it applies at the program level to continuing CGMP training. Suppose there is a deviation between the number of employees who have documented attendance at the annual CGMP refresher training session and the total number of employees who are required by procedure to attend by the end of the calendar year. In this case, the alert level is any number of employees greater than zero, excluding those on medical leave, etc. The supervisor of an employee who has failed to attend by the beginning of the December recess will be alerted by an e-mail message automatically generated by the organization’s learning management system (LMS) (3). Suppose the total number of non-compliant employees is one. Will this deviation occasion a Notice of Event (NoE), investigation, and corrective action and preventive action (CAPA)? No. What about 10 employees? Probably not. What about a hundred? Perhaps. Even if it does, will the CAPA be fulfilled? There have been cases where the corrective action—simply put, getting the remaining employees trained within a month—had to be extended until the middle of February. And there was no preventive action.

Does this mean that an organization can ignore deviations in processes that have been assessed as low risk? Hardly. The business case for an organizational activity is complemented by the compliance case for that same activity. Continuing CGMP training not only periodically reminds employees of the effect of deviations, rework, etc. on the bottom line, but is a regulatory requirement as well. There are several independent assessments of risk for any process or system in regulated industry, no matter how low or high the level of risk. One is the assessment made by various decision makers of the organization, another is the assessment made by regulatory investigators. Both sides are weighing the criticality and complexity of the given process in making their independent risk assessments (4). The decision makers in the organization must constantly be aware of this intricate interaction between their own business risk assessments and the quality risk assessments of the regulatory investigators, and factor the latter into their own calculation of risk.

The quality risk assessment tends to be reflected in the topics to be presented in continuing CGMP training. The topics reflect in part a quality risk assessment made by various decision makers in the organization, perhaps other decision makers than those making the business risk assessments. Those making the quality risk assessment will be addressing the risk to the SISPQ of the product, and how that topic can be presented as a training topic. The level of risk associated with a process or system that is subject to a given regulation is based on the criticality and complexity of that process (5). The risk assessment represents the level of risk as well as the acceptable mitigation of that risk. Take two possible topics for continuing CGMP training, one of a higher level of quality risk and another of a lower level of quality risk. Suppose the choice was to be made between an episode in a higher risk activity such as aseptic processing and an episode in a lower risk activity such as secondary packaging. Then the decision maker(s) should consider the two processes and track and trend other deviations, out-of-spec findings, and investigations. Then the decision maker should prioritize the episodes in terms of the highest risk, and the highest priority example would be emphasized during the training. The International Conference on Harmonisation (ICH) expressed it well, “the level of effort […] of the quality risk management process should be commensurate with the level of risk” (6). And this level of effort includes training about the topics of the quality risk management process. Both kinds of risk assessment, business and quality, must be taken into account for continuing CGMP training.

**REGULATIONS CALL FOR CONTINUING CGMP TRAINING**

FDA regulations call for continuing CGMP training. The regulations for finished pharmaceuticals are quite explicit: “Training in current good manufacturing practice shall be conducted by qualified individuals on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them” (7). Three points in this passage should be highlighted: the training shall be “conducted by qualified individuals,” shall be conducted “on a continuing basis,” and shall address “CGMP requirements applicable to them.”

Some FDA regulations tend to be more implicit. For instance, in the section “Blood And Blood Components,” it is stated that “All personnel shall have capabilities commensurate with their assigned functions, a thorough understanding of the procedures or control operations they
The necessity of continuing training or experience, and adequate information concerning the application of pertinent provisions of this part to their respective functions” (8). The European Union makes a similar point about the need for continuing training in GMPs. “Besides the basic training on the theory and practice of good manufacturing practice, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given…” Health Canada also mandates continuing CGMP training, so that “all personnel are aware of the principles of GMP that affect them, and all personnel receive initial and continuing training relevant to their job responsibilities” (9).

A rationale for continuing CGMP training is provided in several guidances. For example, the *Quality Systems Approach to Pharmaceutical CGMP Regulations* indicates that “continued training is critical to ensure that the employees remain proficient in their operational functions and in their understanding of CGMP regulations” (10). Likewise, the International Conference on Harmonisation (ICH) states, “Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs and GMP as it relates to the employee’s functions” (11).

The usefulness of continuing training has been observed outside the area of GMPs. Continuing training in good clinical practices (GCPs), for example, has been recommended for clinical trials staff, as well as for Institutional Review Board (IRB) members (12).

Hence the FDA regulations provide a mandate for continuing CGMP training. Of course there are interpretive issues regarding these, as any, regulations. As Michael Breggar has correctly put it, “most drug regulations are subject to interpretation” (13). Organizations in the life sciences do not simply react to a regulation; instead there is an intricate interaction between organizational actors at all levels and the various regulations and regulatory regimes, all within a given setting (14). Between an observation of a gap and an organization’s response is a complex decision process. This will occur whether it is a higher level of risk, such as the level of viable particulates in a monitored area, or a lower level of risk, such as one, ten, or a hundred employees failing to attend the annual CGMP refresher training. An observation is typically escalated, triaged, and may or may not become a record of interest in the organization’s quality management system. Whether the observation will or will not become a record of interest depends upon the risk assessment. It is that record that may or may not become the basis of an investigation and root cause analysis. Whether the record is investigated further depends upon (possibly a further) risk assessment. Neither employees nor the organization react to the standard, the regulation—they respond to the observed gap, in terms of risk assessments. The record of the observed gap can also become part of a set of similar records that can be tracked and trended within the quality management system. If necessary, the set itself can be investigated further. Again it is not a matter of reacting to standards, SOPs, or regulations. The organization is responding to the set of excursions, the set of gaps, as reported in the set of records. The conclusion of an investigation can be followed by the development and execution of corrective actions and preventive actions. At each decision node, the decision is based on interpretations and also on risk assessments.

The interpretive aspects and risk assessments of this investigative and remediation process may be more or less explicit in various areas of the life science industry, but the underlying need for interpretation and risk assessment remains. Moreover, since interpretive aspects and risk assessments underlie any organization’s response to compliance issues, no organization is simply reactive to regulations.

**WHO ARE THE QUALIFIED INDIVIDUALS?**

FDA regulations mandate that “Training in current good manufacturing practice shall be conducted by qualified individuals” (15). Likewise, Health Canada requires that “Training is provided by qualified personnel” (16).

As Joanne Cochran and Joseph Nally point out, “Since 211.25(a) requires GMP training to be given by qualified personnel, the company should have a procedure and process for qualifying trainers” (17). An SOP documents the following three things:

1. It indicates the sequence of tasks that make up the process, in this case the steps (or tasks) that make up the process of qualifying a trainer
2. The procedure stipulates the persons or positions that are responsible for executing the tasks
3. Finally, the SOP lists the standards that define the
satisfactory completion of the tasks. In sum, the procedure lists the necessary steps (tasks) that, taken together, are sufficient to produce the desired outcome of the process (18).

**The Qualification of SMEs**

The qualification of trainers is a specific instance of the more general process of qualifying subject matter experts (SMEs). As such, the SOP and process for qualifying trainers will be homologous to the SOP and process for the qualification of SMEs. This is not to say that SMEs can be conflated with trainers. There are substantial differences between the two, even though a master trainer can be considered an expert in the subject matter of training.

Crucial differences exist between the kind of process requiring the qualification of a SME and the kind of process (i.e., a GMP training process) requiring the qualification of a trainer. A SME must be qualified, if the following relevant procedure or process:

- Involves high skill level, complex activity or application of advanced knowledge or logic
- Is performed in the direct manufacturing of a pharmaceutical product
- Involves quality attributes (SISPQ) of the product
- Has serious consequences for the batch, negative impact on the patient, or injury to the operator in the case of error or deviation.

These criteria clearly reflect aspects of criticality and complexity that go into risk assessment. By contrast, a trainer must be qualified to present any CGMP training, regardless of complexity and criticality.

**Approaches to Trainer Qualification**

There are two basic approaches to qualifying CGMP trainers. One is a formal approach, such as a train-the-trainer program; the other is an experiential approach, based on management’s judgment that an employee is qualified to provide training (19).

A GMP train-the-trainer program provides a formalized approach to the selection of candidates for the training, the delivery of the classroom session, the aspiring trainer’s preparation and delivery of a presentation to demonstrate proficiency, and the assessment of the aspiring trainer’s performance (20).

In the case of the experiential approach to the qualification of trainers, management selects the “qualified trainer” based on more or (usually) less explicit criteria and documentation. This approach to trainer qualification is less demanding than the formal approach, including less demanding of resources.

The formal approach to the qualification of trainers has several advantages over the experiential approach. Importantly, it tends to homogenize the delivery of training events. This tends to reduce the variation in subsequent performance across trainees (employees). The formal approach also facilitates root cause analysis in the face of a manufacturing deviation or out-of-spec lab result. When an investigation is called for, the task is to find some element of the manufacturing or lab process, call it A, where the variation in A causes variation (deviation) in a quality attribute of the product B.

The investigation proceeds by eliminating the various elements of the process that might have been the cause of the deviation. Elements that are reviewed include the equipment, the facilities, the utilities, the raw material, the procedure, the employee, etc. One by one, the elements are considered and eliminated from consideration, until (ideally) one remains. That is labeled the “root cause.” When an element has been qualified, it is ensured that it has been installed according to design specifications, it operates in a reliable fashion, and that its output or product has a uniform (and high) quality. Thus the element will not vary from design specifications upon installation. The element will not vary from its specified range during the operation of the system. And its product will not vary from the desired level of quality. Because there has been no variation of the element that has been qualified, it cannot be the cause of the manufacturing deviation or out-of-spec lab result. Through qualification, that element will be removed from consideration in an investigation.

Human error is frequently cited as the root cause of deviations in investigations (21). The deviation is frequently attributed to a training inadequacy on the part of the employee whose performance has failed, causing the deviation. This training inadequacy, in turn, is attributed to an inadequacy of the trainee, the training event, or the trainer, in some combination. However, if three conditions are met (the trainer has been rigorously qualified in terms of the formal approach, the qualification has been
periodically monitored, and tracking and trending of other deviations does not show recurrences), then the trainer and the training event can be removed from consideration in an investigation. It would be implausible to remove the trainer and the training event from root cause consideration if the trainer had been decreed “qualified” by management through the experiential approach.

**Staffing Considerations**

It is most desirable that a qualified trainer, who is also a SME in the topic to be trained, is available to deliver the training. What if such an individual is not available, either in-house or externally? In that case, there seem to be three staffing options that will meet regulatory requirements for CGMP training to be delivered by “qualified individuals.” One option is to have a SME become qualified as a trainer. As Saundra Williams stresses, “subject matter experts require training in adult learning theory and training techniques before they can adequately train others.” As a second point, she notes, “subject matter experts tend to know much more information than they need to convey. This causes them to overload the learner with information that is unrelated to job needs.” Third, she continues, “ineffective training delivery [by SMEs] wastes dollars invested in instructors, training materials, and employee time.” Finally, she points out that, “SMEs who have not been given enough support in the delivery of technical training may cause employees to feel demoralized because they cannot apply the skills on the job” (22).

A second option is to have a qualified trainer become proficient as a SME on the topic to be trained. Linda Elengold cautions, however, that, “it can take the generic trainer weeks, if not months, to get up to speed on a specific process or skill.” She concludes, “many employers believe that it is harder to turn a professional trainer into a technically savvy trainer than it is to turn a SME into a trainer” (23).

But there is a third option. Vesper points out that, “sometimes it is difficult to find good trainers who also have solid experience or knowledge in a particular technical area.” He goes on to say, “that is an excellent opportunity for co-teaching: an experienced instructor helping to lead the formal sections of the course and the expert serving as a resource to relate experiences and answer questions.” He concludes that “if a co-teaching approach is used, both people should be qualified as a team, and that should be provided for in your training SOP” (24). Developing a training team consisting of a qualified trainer and a SME is a most effective way to address the staffing challenge in the short term.

**APPLICABLE CGMP REQUIREMENTS**

The FDA regulations stipulate that the training will “assure that employees remain familiar with CGMP requirements applicable to them.” What are those “applicable requirements”? Conceptualize the regulatory framework as a pyramid, with the CGMPs at the top, corporate policies making up the next tier, divisional standards as a further tier, and local SOPs as the lower tier (25). Then the applicable requirements are those that filter down from the CGMPs and are refracted in the local procedures (see Figure).

Topics for continuing CGMP training include not only the regulations in 21 CFR 211, as refracted to the local level, but also any “written procedures required by these regulations, as they relate to the employee’s functions” (26). Those written procedures include the following (see Table I).

Suggested topics for continuing CGMP training are also given in several guidances. For example, the *Quality Systems Approach to Pharmaceutical CGMP Regulations* indicates that “training should address the policies, processes, procedures, and written instructions related to operational activities, the product/service, the quality...
<table>
<thead>
<tr>
<th>Regulation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>§211.22(d)</td>
<td>Responsibilities of quality control unit</td>
</tr>
<tr>
<td>§211.56</td>
<td>Sanitation</td>
</tr>
<tr>
<td>§211.67(b)</td>
<td>Equipment cleaning and maintenance</td>
</tr>
<tr>
<td>§211.80(a)</td>
<td>Control of components, containers, and closures</td>
</tr>
<tr>
<td>§211.100</td>
<td>Production and process controls</td>
</tr>
<tr>
<td>§211.101</td>
<td>Charge-in of components</td>
</tr>
<tr>
<td>§211.110(a)</td>
<td>In-process sampling and testing</td>
</tr>
<tr>
<td>§211.113</td>
<td>Control of microbiological contamination</td>
</tr>
<tr>
<td>§211.115(a)</td>
<td>Reprocessing</td>
</tr>
<tr>
<td>§211.122(a)</td>
<td>Materials examination and usage criteria</td>
</tr>
<tr>
<td>§211.125(f)</td>
<td>Labeling issuance</td>
</tr>
<tr>
<td>§211.130</td>
<td>Packaging and labeling operations</td>
</tr>
<tr>
<td>§211.142</td>
<td>Warehousing procedures</td>
</tr>
<tr>
<td>§211.160(a)</td>
<td>Laboratory controls</td>
</tr>
<tr>
<td>§211.165(c)</td>
<td>Testing and release for distribution</td>
</tr>
<tr>
<td>§211.166(a)</td>
<td>Stability testing</td>
</tr>
<tr>
<td>§211.167</td>
<td>Special testing requirements</td>
</tr>
<tr>
<td>§211.176</td>
<td>Penicillin contamination</td>
</tr>
<tr>
<td>§211.180(f)</td>
<td>Records and reports</td>
</tr>
<tr>
<td>§211.198(a)</td>
<td>Complaint files</td>
</tr>
<tr>
<td>§211.204</td>
<td>Returned drug products</td>
</tr>
</tbody>
</table>
system, and the desired work culture (e.g., team building, communication, change, behavior)” (27).

Likewise, Sterile Drug Products Produced by Aseptic Processing suggests that “fundamental training topics should include aseptic technique, cleanroom behavior, microbiology, hygiene, gowning, patient safety hazards posed by a non-sterile drug product, and the specific written procedures covering aseptic manufacturing area operations” (28). Also, the Guideline for Quality Assurance in Blood Establishments suggests that training topics may be derived from a review of “management observations, proficiency test results, competency evaluations, technical changes, error/accident reports, complaints, QA audits, and problems discovered at critical control points identified in each system within the establishment’s total operation” (29).

Another source of topics for continuing CGMP training is the set of FDA warning letters, accessible from www.fda.gov. This is an extensive compilation of GXP deviations of all sorts that can be mined for topics. There are two problems that emerge when using these resources.

First, the warning letters refer to companies other than that of the training audience, which tends to blunt the significance of non-compliance, no matter how serious. For striking examples, FDA inspected the Peanut Corporation of America (PCA) in early January 2009 and found “one environmental swab collected on 01/10/09 from the finished product cooler floor was found positive for Salmonella. The swab location was within three feet of pallets of finished product.” Moreover “mold was observed growing on the ceiling and walls in the firm’s cooler used for finished product storage. In addition, water stains were observed running down from the cooling unit fans in the cooler. On 01/10/09, pallets of finished product were stored directly beneath this unit” (30). The training audience can easily say, “Yes, these are terrible conditions, but they took place in Georgia.”

The second problem is that many times the warning letters do not provide the level of detail needed to develop compelling CGMP training. This is the case even when the warning letter is augmented by newspaper accounts. Again this tends to blunt the significance of non-compliance. It is very clear that something was seriously amiss in the PCA’s environmental monitoring program, but it is very hard to pin that down to make training points.

Still another source of topics is the organization’s own documentation of deviations, investigations, CAPAs, and product quality complaints, as captured in the quality management system. This documentation can be reviewed on a periodic basis, say quarterly or even monthly. The selected record can be worked up and presented in a training module. These records do not suffer from either of the shortcomings noted for the FDA warning letters. The organization’s documentation refers to the training audience’s own systems, and some members of the audience may have been involved in the investigation and remediation process. Secondly, the very demands for compliance and documentation in the organization’s investigation and remediation SOPs should ensure an adequate level of detail to make training points.
Take a illustrative example, one that might be a suitable topic for a quarterly CGMP training session. Recently, warehouse staff had trouble correctly filling out a particular form. Supervision caught the problem several times, while countersigning the document. Then supervision missed one, and it was recorded in the quality management system. Management was alerted, and requested an investigation of the problem—was it a matter of employee training, procedure, form design, or what?

During the investigation, training records were reviewed, and each of the warehouse employees had been trained on the current version of the SOP by a qualified trainer. The SOP was reviewed. It looked straightforward on its face, and because it also covered two other forms for which no problems had been observed, it was given a clean bill of health. The form itself was reviewed, in terms of the following checklist:

• **Who is the owner of the form?** If there was no specified owner of the form, no one would be responsible for the integrity of the form, and perhaps more important, anyone could make changes to the form. These uncontrolled changes result in incoherence of the form.

• **Were user requirements gathered?** Gathering user requirements during planning for the form should trump managerial decree for content and structure. User requirements include answers to the following:
  • Who fills out the form?
  • What is the form’s purpose?
  • What is the time frame for using the information in the form?
  • Are there duplicate users of the form?

• **What is the structure and flow of the form?** The structure and flow of the form should comprise a linear progression, upper left to lower right.

• **Is the form focused?** The form should be succinct rather than wordy.

• **Are there instructions for the form?** If there are instructions, they should be included on a separate section or separate page, rather than interspersed within the form itself.

• **Was there expert review of the form?** Critical review by SMEs can frequently point out problematic aspects of a form, which should be addressed before finalizing the document.

• **Was there usability testing of the form?** It is critical to pilot the penultimate draft of the form then make revisions in light of the experiences and criticisms of a sample of end users (31).

During the review of the form, it became clear that there were several serious content and formatting issues. When the form was redesign, the warehouse staff’s trouble filling out the form ended. The problem seems to have been resolved. It is worth noting that re-training of the warehouse employees was not required, since training was not identified as the root cause of the problem (32), but the employees had to be trained on the rectified form.

This illustrative account could be proposed to the training council or other appropriate group, and, if approved, could be worked up into a continuing CGMP training module. It would be of interest to the organization’s staff, because it refers to their warehouse, they may know the form in question, they may know some of the employees who were involved in the problem, and they will be pleased to see the satisfactory outcome of the investigation.

Perhaps the best approach to sources of topics for continuing CGMP training is a combination of local problems.
<table>
<thead>
<tr>
<th>Regulation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>§211.192</td>
<td>Production record review</td>
</tr>
<tr>
<td>§211.160</td>
<td>Laboratory controls</td>
</tr>
<tr>
<td>§211.100</td>
<td>Written procedures; deviations</td>
</tr>
<tr>
<td>§211.22</td>
<td>Responsibilities of quality control unit</td>
</tr>
<tr>
<td>§211.42</td>
<td>Design and construction features</td>
</tr>
<tr>
<td>§211.84</td>
<td>Testing and approval or rejection of components, containers, and closures</td>
</tr>
<tr>
<td>§211.110</td>
<td>Sampling and testing of in-process materials and drug products</td>
</tr>
<tr>
<td>§211.113</td>
<td>Control of microbiological contamination</td>
</tr>
<tr>
<td>§211.165</td>
<td>Testing and release for distribution</td>
</tr>
<tr>
<td>§211.188</td>
<td>Batch production and control records</td>
</tr>
</tbody>
</table>

gleaned from records in the organization’s quality management system, with direction provided by the most serious compliance problems, as indicated by FDA warning letters (33) (see Table II). For instance, one recurring topic from fiscal years 2005 through 2008 has been 21 CFR 211.22, Responsibilities of Quality Control Unit. Should the organization’s records provide any instances of such problems, the FDA warning letters might give additional weight to the training points.

A final point about applicable CGMP requirements is the relevance and effectiveness of particular CGMP training for various groups within an organization’s workforce. In Q9, Quality Risk Management, the ICH has suggested that a potential use of quality risk management principles and tools may be “to determine the appropriateness of [...] ongoing training sessions based on education, experience and working habits of staff” (34). Trainees can be grouped according to their task assignments. For example, employees who check batch records need not be given the same continuing CGMP training module as operators, even though both groups may be governed by the same broad set of procedures. Their workplace focus is much different. Likewise, ICH recommends that the appropriateness of continuing training be determined by “a periodic assessment of previous training (e.g., its effectiveness)” (35).

**LOGISTICS OF CONTINUING CGMP TRAINING**

Having discussed the regulatory requirements for continuing CGMP training, the necessity of using qualified trainers to deliver the training, and the topics that could make up the training content, it is time to turn to the logistics of this training. The main logistical question is: How frequently should this continuing training be scheduled?

FDA regulations do not stipulate the frequency of continuing training, but recommendations are available in guidances. For example, the Current Good Manufacturing Practice for Medical Gases indicates that, “FDA recommends that CGMP training not be conducted in one massive training session. Rather, it should be presented in smaller more manageable sessions held throughout the year, or at a minimum be held once a year” (36). Speaking at an FDA workshop, compliance officer Duane Sylvia suggested that, “CGMP training should be revisited at frequent intervals and needs to be conducted by qualified individuals.” He continued “Conducting CGMP training once a year is not recommended, but instead should be presented in smaller more manageable portions, presented throughout the year with documentation of the type, time, and attendance of each session” (37).

Some regulated organizations have developed very elaborate schemes to schedule continuing CGMP training. One example will suffice. An organization required each employee to attend day-long refresher training at a specified location on the first Monday of the employee’s birth month. There was one makeup day a year for employees who missed their scheduled date. The training agenda was fixed for the entire year, regardless of intervening events. It incorporated OSHA, CGMP, business ethics, and other refresher training, as well as a “Meet the CEO” session. Given the packed agenda, less than an hour was devoted to CGMP topics. Birthday cake was provided to each attendee. Nonetheless, this scheme was simply a variant of the “one hour, once a year” CGMP training schedule.

Regarding industry practices, James Vesper has stated that “most companies conduct formal GMP training or reinforcement training at least annually; some do it twice a year; a few do it quarterly” (38). There are business considerations as well as regulatory issues here. More generally, John McConnell has indicated “How often the training course is to be conducted depends on several factors, including:

- Employee availability
- Total number of current employees to be trained
- Maximum size of training classes and method
- Required time to conduct training
- Projected future training population” (39).

**CONCLUSION**

This article addressed continuing CGMP training in four sections. The first section reviewed the statements that FDA and other regulatory bodies have made in regulations and guidances regarding continuing CGMP training. The role that interpretation and risk assessment plays in an organization’s response to gaps (deviations) between the statements and ongoing behavior was stressed. The second section considered the “qualified individuals” that deliver this continuing training, including similarities and differences between qualification of trainers and
qualification of SMEs. A formal approach to qualifying trainers such as a CGMP train-the-trainer program was compared to an experiential approach such as management’s judgment that an employee is qualified to provide training. The experiential approach is cheaper than the formal approach, but the formal approach has the merit of reducing variation in employee performance, as well as facilitating root cause analysis in case of deviations. Also, various staffing options were examined. The third section reviewed topics that are suitable for continuing CGMP training. Sources included CGMP regulations in 21 CFR 211, written procedures required by these regulations, topics mentioned in several FDA guidances, FDA warning letters, and the organization’s own records of deviations, investigations, CAPAs, and product quality complaints. The final section addressed the logistics of such training, including the frequency with which CGMP training should be delivered, concluding that FDA recommends training more frequently than just an annual basis.

ACKNOWLEDGMENTS
The author would like to thank his colleagues J.C. and R.M. for helpful comments.

ENDNOTES
1. See OSHA, 29 CFR 1910.134(k) Respiratory Protection, “The employer [is required] to provide effective training to employees who are required to use respirators. The training must be comprehensive, understandable, and recur annually, and more often if necessary.” See also § 1910.134(k)(5), “Retraining shall be administered annually.”
3. On the one hand, such an e-mail message would be exempt from Part 11 considerations; see G. Welty, “Strategy and Tactics of Training Recordkeeping,” Journal of GXP Compliance, Volume 12, Number 3, April 2008; reprinted in The ADDIE Model, Duluth, MN: Advanstar (2009), pp. 40-43. Among the few training related predicate rules that are covered by 21 CFR 11, Electronic Records; Electronic Signatures, is 21 CFR 111.14(b)(2), which stipulates “Documentation of training, including the date of the training, the type of training, and the person(s) trained,” relating to GMPs for Dietary Supplements. [Published in the Federal Register, Vol. 72, No. 121, June 25, 2007, p. 34810] On the other hand, the message itself can include the proviso that “This message is not a GMP document; for GMP purposes, refer to the source document in the LMS,” etc.
6. ICH, Q9, Quality Risk Management, op. cit., p. 2.
7. 21 CFR 211.25(a), Personnel qualifications.
8. 21 CFR 606.20, Personnel. The relevant phrase is “adequate information concerning the application of pertinent provisions of this part to their respective functions.”
10. FDA, Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations, September 2006, p. 13. Thus a business rationale as well as a compliance rationale can be made for continuing training. For the business rationale, see Anne Garstka and Donald E. Hagman, “The Benefits of Training Right,” SP Forum March 9, 2000, “training must be continuous. By providing continuous training, pharmaceutical companies instill good habits that lead to safe, effective products and higher profits.”
12. Regarding clinical trials staff, see Barry Strack, “Training for the...


14. Interpretive issues about observations arise on the regulatory side as well. Consider the FDA’s 483 observation to MedImmune dated 29 March 2007 “on March 28, 2007 […] an operator was observed cleaning his/her personal prescription glasses in the IS0 Class […] area.” Compare that to FDA’s warning letter to MedImmune dated 24 May 2007 “On March 28, 2007, an operator was observed removing his/her safety glasses, then removing and cleaning his/her prescription type glasses, thus allowing for skin to be exposed.” These are available at www.fda.gov/downloads/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/UCM056161.pdf and www.fda.gov/ICECI/EnforcementActions/ WarningLetters/2017/ucm1076398.htm

15. 21 CFR 211.25(a), Personnel qualifications.


19. See Cochran and Nally, op cit., p. 31: “Minimum requirements for trainers may include some formal education (e.g., Train-the-Trainer course) or experience in presenting training…”


21. As Breggar, op. cit., p. 26 has aptly put it, “Generally speaking, most FDA citations appear technical. But their root cause is nearly always managerial issues that impede the performance of people.”


24. J. Vesper “Defining Your GMP Training Program with a Training Procedure,” BioPharm (Eugene, OR), (Nov 2000), p. 30. This is a short term option; in the longer term, management will likely prefer a SME becoming a qualified trainer, or a qualified trainer becoming a subject matter expert.


26. 21 CFR Sec. 211.25(a), Personnel qualifications.


30. Available at www.fda.gov/downloads/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/UCM109834.pdf These are but two of an extensive series of observations.


34. ICH, *Q9, Quality Risk Management*, op. cit., p. 15.


*CDER Inspection Tips*, Salt Lake City: Master Control, 2006, p. 4: “Training should not be a one-shot deal. It has to be ongoing and dynamic.”


**ARTICLE ACRONYM LISTING**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPA</td>
<td>Corrective Action and Preventive Action</td>
</tr>
<tr>
<td>CGMP</td>
<td>Current Good Manufacturing Practice</td>
</tr>
<tr>
<td>FDA</td>
<td>US Food and Drug Administration</td>
</tr>
<tr>
<td>GCPs</td>
<td>Good Clinical Practices</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LMS</td>
<td>Learning Management System</td>
</tr>
<tr>
<td>NEO</td>
<td>New Employee Orientation</td>
</tr>
<tr>
<td>NoE</td>
<td>Notice of Event</td>
</tr>
<tr>
<td>OSHA</td>
<td>Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>PCA</td>
<td>Peanut Corporation of America</td>
</tr>
<tr>
<td>SISPQ</td>
<td>Safety, Identity, Strength, Purity, and Quality</td>
</tr>
<tr>
<td>SMEs</td>
<td>Subject Matter Experts</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
</tbody>
</table>

**ABOUT THE AUTHOR**

Gordon Welty, Ph.D., has been designing, developing, facilitating, evaluating, and managing technical and regulatory training programs in the healthcare and pharmaceutical industries for more than 20 years. Contact Gordon at gwelty@wright.edu.